Dr. Sharad Khurana
Claim this profileUniversity of Arizona Cancer Center
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
4 reported clinical trials
14 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
t(9;22) translocation positive
FLT3 positive
2Acute Myeloid Leukemia
t(9;22) translocation positive
FLT3 positive
Affiliated Hospitals
Clinical Trials Sharad Khurana is currently running
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting1 award Phase 217 criteria
Screening Tool
for Myeloid Cancer
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Recruiting0 awards Phase 21 criteria
More about Sharad Khurana
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sharad Khurana has experience with
- Azacitidine
- Venetoclax
- Cytarabine
- Daunorubicin Hydrochloride
- TAS1440
- ATRA
Breakdown of trials Sharad Khurana has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorder
Acute Myeloid Leukemia or Myelodysplasia-Related Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sharad Khurana specialize in?
Sharad Khurana focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved t(9;22) translocation positive patients, or patients who are FLT3 positive.
Is Sharad Khurana currently recruiting for clinical trials?
Yes, Sharad Khurana is currently recruiting for 2 clinical trials in Tucson Arizona. If you're interested in participating, you should apply.
Are there any treatments that Sharad Khurana has studied deeply?
Yes, Sharad Khurana has studied treatments such as Azacitidine, Venetoclax, Cytarabine.
What is the best way to schedule an appointment with Sharad Khurana?
Apply for one of the trials that Sharad Khurana is conducting.
What is the office address of Sharad Khurana?
The office of Sharad Khurana is located at: University of Arizona Cancer Center, Tucson, Arizona 85719 United States. This is the address for their practice at the University of Arizona Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.